Ang Li - Concepedia

Author

Ang Li

Bristol-Myers Squibb (United States)ORCID

Also Known As

Ang Li, Li, Ang

172

Publications

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Moffitt Cancer Center Sarah Cannon Johns Hopkins University Tennessee Oncology

About

Ang Li is an author at Bristol-Myers Squibb (United States) specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	1K
2	Health Sciences	4	4	129
3	Engineering	3	3	66
4	Chemical Engineering	2	2	41
5	Public Health	1	1	92

Ang Li

Publications

4.8K

Citations

H-Index

Page 1

	Year	Citations
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057) Leora Horn, David R. Spigel, Everett E. Vokes, Journal of Clinical Oncology	2017	857
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study Scott Gettinger, Leora Horn, David M. Jackman, Journal of Clinical Oncology	2018	731
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer Hossein Borghaei, Scott Gettinger, Everett E. Vokes, Journal of Clinical Oncology	2021	614
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis Scott Antonia, Hossein Borghaei, Suresh S. Ramalingam, The Lancet Oncology OncologyFour-year SurvivalImmune Checkpoint InhibitorCancer TreatmentPooled Analysis	2019	361
Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China Zhigang Ren, Jianwen Jiang, Haiyang Xie, Oncotarget	2017	227
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153 David Waterhouse, Edward B. Garon, Jason C. Chandler, Journal of Clinical Oncology	2020	223
MicroRNA Alterations of Pancreatic Intraepithelial Neoplasias Jun Yu, Ang Li, Seung‐Mo Hong, Clinical Cancer Research	2011	208
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153) David R. Spigel, Michael McCleod, Robert M. Jotte, Journal of Thoracic Oncology Checkmate 153OncologyCancer ManagementOutcomes ResearchPatient-reported Outcome	2019	184
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations Enriqueta Felip, Andrea Ardizzoni, Tudor–Eliade Ciuleanu, European Journal of Cancer	2020	155
Fascin Is Regulated by Slug, Promotes Progression of Pancreatic Cancer in Mice, and Is Associated With Patient Outcomes Ang Li, Jennifer P. Morton, Yafeng Ma, Gastroenterology	2014	123

Page 1